With SPACs' high tide long gone, Blue Water ditches second blank check voyage

2024-06-17
疫苗并购IPO
The SPAC waters have been choppy for a few quarters, and the leaders of Blue Water Vaccines are joining the wave of blank-check operators ditching plans to dock their boat on Wall Street. While the Blue Water duo of Joseph Hernandez and Jon Garfield was successful in getting their first SPAC to merge with a biotech, testosterone drug maker Clarus Therapeutics, and also take their own biotech public in February, they have decided to back out of the SPAC market, following the suit of many others. Blue Water Vaccines CEO Hernandez and CFO Garfield had filed their second SPAC, aptly named Blue Water Acquisition II, for a $75 million IPO in October 2021, a month after their first blank check completed its merger with Clarus, taking the Illinois biotech public with $25.3 million in gross proceeds. But they have pulled the IPO plans for their second attempt, according to an SEC filing Thursday morning. They had planned to merge with a life sciences or pharmaceutical services company in the US or Europe. Clarus, which markets the drug Jatenzo, is a mere shell of the typical $10 that most SPACs trade at. Since landing on Nasdaq last autumn, Clarus $CRXT has sunk to 28 cents per share. Meanwhile, Blue Water Vaccines raised $20 million in its IPO back in February, one of very few biotechs to go public in the market doldrums of 2022. The preclinical company, looking at vaccines for universal flu, norovirus, rotavirus and malaria vaccines, priced at $9 but has since fallen to about $2.50 per share $BWV . The decision to pull the second Blue Water SPAC comes after Innovatus Life Sciences Acquisition withdrew its $175 million IPO two weeks ago. But the SPAC merger window isn’t completely shut. Two deals were announced in recent weeks, with a company attempting to revive an old Amgen cardio drug and a Phase I biotech in the renal and inflammatory disease space.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。